Stock Price Quote

DR AGARWALS EYE HOSPITAL LTD.

NSE : NABSE : 526783ISIN CODE : INE934C01018Industry : Hospital & Healthcare ServicesHouse : Private
BSE4345.4519.9 (+0.46 %)
PREV CLOSE ( ) 4325.55
OPEN PRICE ( ) 4290.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3025
TODAY'S LOW / HIGH ( )4290.00 4450.00
52 WK LOW / HIGH ( ) 28007300
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-04 1994
Management Info
Amar Agarwal - Chairman Amar Agarwal - Managing Director
Registered Office

Address 3rd Floor, Buhari Towers, No.4, Moores Road,Off. Greams Road,Near Asan Memorial School,
Chennai,
Tamil Nadu-600006

Phone 044-43787777 / 78

Email info@dragarwal.com

Website www.dragarwal.com

Registrars Details
Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai
Listing : BSE

NEWS

19Mar Dr Agarwals Eye Hospital commences ope
Dr Agarwals Eye Hospital has commenced operation of a new branch located..
29Jan Clarification sought from Dr Agarwals
The Exchange has sought clarification from Dr Agarwals Eye Hospital Ltd..
30Sep Dr. Agarwal’s Eye Hospital informs abo
As per the SEBI (Prohibition of Insider Trading) Regulations, 2015 and t..
28Sep Dr.Agarwals Eye Hospital informs about
Dr.Agarwals Eye Hospital has informed that the Exchange has received Dis..
23Sep Dr. Agarwal’s Eye Hospital informs abo
Pursuant to Regulation 30 read with Para B of Part A of Schedule III of..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit104463.6
Gross Profit 140.6 622.5
Operating Profit 279.3960.3
Net Sales 951.13193

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Apollo Hospital Ent. (BSE)
peergroup  6425.65 (2.82%)
M.Cap ( in Cr)92390.99
Kovai Medical Center (BSE)
peergroup  5394.90 (1.34%)
M.Cap ( in Cr)5903.24
Max Healthcare Inst (BSE)
peergroup  1088.15 (6.95%)
M.Cap ( in Cr)105783.64
Jupiter Life Line (BSE)
peergroup  1592.55 (4.28%)
M.Cap ( in Cr)10441.72
Krsnaa Diagnostics (BSE)
peergroup  789.05 (4.64%)
M.Cap ( in Cr)2547.82

Shareholding Pattern

PROMOTERS 71.9%
NON-INSTITUTION 26.23%
MUTUAL FUNDS/UTI 0.05%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Dr Agarwals Eye Hospital Ltd.

Dr Agarwals Eye Hospital Ltd. was incorporated in the year 1994. Its today's share price is 4345.45. Its current market capitalisation stands at Rs 2042.36 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3193 Cr and Total Income of Rs.3244.8 Cr. The company's management includes Meenakshi Jayaraman, Latha Ramanathan, Balakrishnan Venkatraman, Adil Agarwal, Athiya Agarwal, Amar Agarwal, Amar Agarwal.

It is listed on the BSE with a BSE Code of 526783 , NSE with an NSE Symbol of and ISIN of INE934C01018. It's Registered office is at 3rd Floor, Buhari Towers, No.4, Moores Road,Off. Greams Road,Near Asan Memorial SchoolChennai-600006, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, MK Dandekar & Co, MK Dandeker & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.